Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Triapine in combination with radiation therapy for recurrent glioblastoma or astrocytoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant
• Diffuse Hemispheric Glioma H3 G34-mutant
• Diffuse Midline Glioma H3 K27m-mutant
• Glioblastoma Idh-wildtype

Drugs mentioned

• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Status: SUSPENDED